Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4
2003 · Advances in experimental medicine and biology · 216 citations
https://doi.org/10.1007/978-1-4615-0081-0_21
A
Ana Rovira
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
377
Papers
6.7K
Citations
44
h-index
101
i10-index
Ana Rovira is an academic researcher from Instituto de Salud Carlos III. The author has contributed to research in topics: Cancer Cells and Metastasis & HER2/EGFR in Cancer Research & Lung Cancer Research Studies. The author has an h-index of 44, co-authored 321 publications.
ORCID: 0000-0003-1301-2599Papers by this author
worksNuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
2011 · Annals of Oncology · 177 citations
https://doi.org/10.1093/annonc/mdr361
A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples
2017 · PLoS ONE · 145 citations
https://doi.org/10.1371/journal.pone.0170632
Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
2013 · Clinical Cancer Research · 135 citations
https://doi.org/10.1158/1078-0432.ccr-13-1330
NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival
2019 · Clinical Cancer Research · 130 citations
https://doi.org/10.1158/1078-0432.ccr-18-2365
Snail1-Expressing Fibroblasts in the Tumor Microenvironment Display Mechanical Properties That Support Metastasis
2014 · Cancer Research · 124 citations
https://doi.org/10.1158/0008-5472.can-14-1903
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat